| Fabry Disease
Fabrazyme vs Galafold
Side-by-side clinical, coverage, and cost comparison for fabry disease.Deep comparison between: Fabrazyme vs Galafold with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGalafold has a higher rate of injection site reactions vs Fabrazyme based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Galafold but not Fabrazyme, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fabrazyme
Galafold
At A Glance
IV infusion
Every 2 weeks
Enzyme replacement therapy
Oral
Every other day
Pharmacological chaperone (alpha-Gal A)
Indications
- Fabry Disease
- Fabry Disease
Dosing
Fabry Disease 1 mg/kg body weight infused every two weeks as an IV infusion; initial infusion rate 0.25 mg/min (15 mg/hour); for patients >=30 kg, rate may be increased in increments of 0.05-0.08 mg/min with each subsequent infusion as tolerated.
Fabry Disease 123 mg orally once every other day; swallow capsule whole on an empty stomach (no food or caffeine for at least 2 hours before and 2 hours after dosing).
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, rash, pain in extremity, myalgia, lower respiratory tract infection, pain, back pain, hypertension, pruritus, tachycardia, excoriation, increased blood creatinine, tinnitus, dyspnea, fall, burning sensation, anxiety, depression, wheezing, hypoacusis, chest discomfort, fungal infection, viral infection, hot flush.
Serious Hypersensitivity reactions including anaphylaxis, infusion-associated reactions.
Postmarketing Cardiorespiratory arrest, cardiac failure, myocardial infarction, anaphylaxis, angioedema, bronchospasm, cerebrovascular accident, respiratory failure, renal failure, leukocytoclastic vasculitis.
Most common (>=10%) Headache, nasopharyngitis, urinary tract infection, nausea, pyrexia
Postmarketing Angioedema
Pharmacology
Agalsidase beta provides an exogenous source of alpha-galactosidase A; it is internalized and transported into lysosomes where it exerts enzymatic activity and reduces accumulated globotriaosylceramide (GL-3) in Fabry disease patients.
Migalastat is a pharmacological chaperone that reversibly binds to the active site of alpha-galactosidase A (alpha-Gal A), stabilizing the enzyme and restoring its trafficking from the endoplasmic reticulum to the lysosome, where it degrades glycosphingolipid substrates GL-3 and lyso-Gb3 in patients with amenable GLA variants causing Fabry disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fabrazyme
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Galafold
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Fabrazyme
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Galafold
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fabrazyme
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Galafold
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FabrazymeView full Fabrazyme profile
GalafoldView full Galafold profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.